JP6789283B2 - 改変酵母−ブラキュリー免疫療法組成物 - Google Patents

改変酵母−ブラキュリー免疫療法組成物 Download PDF

Info

Publication number
JP6789283B2
JP6789283B2 JP2018505476A JP2018505476A JP6789283B2 JP 6789283 B2 JP6789283 B2 JP 6789283B2 JP 2018505476 A JP2018505476 A JP 2018505476A JP 2018505476 A JP2018505476 A JP 2018505476A JP 6789283 B2 JP6789283 B2 JP 6789283B2
Authority
JP
Japan
Prior art keywords
yeast
bracury
cancer
bracully
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018505476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522041A (ja
JP2018522041A5 (enExample
Inventor
エイチ． キング、トーマス
エイチ． キング、トーマス
グオ、ジミン
シュロム、ジェフリー
パレナ、クラウディア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2018522041A publication Critical patent/JP2018522041A/ja
Publication of JP2018522041A5 publication Critical patent/JP2018522041A5/ja
Application granted granted Critical
Publication of JP6789283B2 publication Critical patent/JP6789283B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018505476A 2015-08-03 2016-08-01 改変酵母−ブラキュリー免疫療法組成物 Active JP6789283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200497P 2015-08-03 2015-08-03
US62/200,497 2015-08-03
PCT/US2016/044977 WO2017023840A1 (en) 2015-08-03 2016-08-01 Modified yeast-brachyury immunotherapeutic compositions

Publications (3)

Publication Number Publication Date
JP2018522041A JP2018522041A (ja) 2018-08-09
JP2018522041A5 JP2018522041A5 (enExample) 2019-09-12
JP6789283B2 true JP6789283B2 (ja) 2020-11-25

Family

ID=56618277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505476A Active JP6789283B2 (ja) 2015-08-03 2016-08-01 改変酵母−ブラキュリー免疫療法組成物

Country Status (11)

Country Link
US (1) US11065313B2 (enExample)
EP (1) EP3331552B1 (enExample)
JP (1) JP6789283B2 (enExample)
KR (1) KR102833272B1 (enExample)
CN (1) CN108348586B (enExample)
AU (1) AU2016303525B2 (enExample)
CA (1) CA2994272C (enExample)
HK (1) HK1249431A1 (enExample)
IL (1) IL257208B (enExample)
TW (1) TWI748957B (enExample)
WO (1) WO2017023840A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907560C (en) 2013-03-19 2021-12-07 Timothy C. Rodell Yeast-based immunotherapy for chordoma
WO2015157639A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CA2994694A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
WO2019222073A1 (en) * 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US20220023348A1 (en) 2018-11-28 2022-01-27 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same
WO2023172922A1 (en) * 2022-03-08 2023-09-14 Immunitybio, Inc. Intratumorally injected yeast vaccine
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
WO1999018980A1 (en) 1997-10-10 1999-04-22 Meyer Pharmaceuticals, Llc Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
JP2004527450A (ja) 2000-04-06 2004-09-09 シーア ファーマスーティカルズ エルエルシー 微生物送達システム
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2898163C (en) 2002-12-16 2016-10-11 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20060009404A1 (en) 2004-07-09 2006-01-12 Williams Jason R Tumor ablation in combination with pharmaceutical compositions
EP2371381A3 (en) 2005-07-11 2012-07-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
EP2468296A3 (en) 2006-02-02 2013-12-04 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
EP2004666B1 (en) 2006-03-27 2014-09-03 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
SG10201405420QA (en) 2007-02-02 2014-10-30 Globeimmune Inc Methods for producing yeast-based vaccines
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
RU2505313C2 (ru) 2007-03-19 2014-01-27 Глоубиммьюн, Инк. Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
WO2009042642A2 (en) * 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
US10383924B2 (en) * 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en) 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US8877205B2 (en) 2011-02-12 2014-11-04 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
KR102046449B1 (ko) 2011-03-17 2019-11-19 글로브이뮨 효모-브라큐리 면역요법 조성물
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
WO2013025972A1 (en) * 2011-08-17 2013-02-21 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
CA2907560C (en) 2013-03-19 2021-12-07 Timothy C. Rodell Yeast-based immunotherapy for chordoma

Also Published As

Publication number Publication date
CN108348586B (zh) 2022-03-15
JP2018522041A (ja) 2018-08-09
IL257208A (en) 2018-03-29
KR102833272B1 (ko) 2025-07-10
WO2017023840A1 (en) 2017-02-09
IL257208B (en) 2021-10-31
CA2994272A1 (en) 2017-02-09
AU2016303525B2 (en) 2021-01-21
CN108348586A (zh) 2018-07-31
AU2016303525A1 (en) 2018-03-15
US11065313B2 (en) 2021-07-20
CA2994272C (en) 2023-08-22
TWI748957B (zh) 2021-12-11
KR20180054587A (ko) 2018-05-24
TW201716574A (zh) 2017-05-16
EP3331552A1 (en) 2018-06-13
US20180214525A1 (en) 2018-08-02
EP3331552B1 (en) 2021-01-27
HK1249431A1 (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
JP6571822B2 (ja) 酵母−ｍｕｃ１免疫療法用組成物およびその使用
JP6580733B2 (ja) 酵母−ブラキュリ免疫治療組成物
JP6789283B2 (ja) 改変酵母−ブラキュリー免疫療法組成物
NZ724797B2 (en) Yeast-brachyury immunotherapeutic compositions
HK1192141A (en) Yeast-brachyury immunotherapeutic compositions
HK1192141B (en) Yeast-brachyury immunotherapeutic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201102

R150 Certificate of patent or registration of utility model

Ref document number: 6789283

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250